New York City–based Definium Therapeutics has reached a pivotal inflection point in the rapidly evolving landscape of psychedelic medicine. Following…
Read More
The MIND Diet May Slow Age-Related Brain Atrophy and Cognitive Decline According to Recent Long-Term Study
Emerging research published in the Journal of Neurology, Neurosurgery & Psychiatry suggests that a specific dietary regimen—the Mediterranean-DASH Intervention for…
Read MoreBefore its recent Phase 3 LSD win, Definium modeled up to $70,000 a year for a therapy that could fill a clinical shift
The landscape of psychiatric medicine is undergoing a profound transformation as pharmaceutical companies transition from chronic, daily-dosing regimens to high-intensity,…
Read More
Before its recent Phase 3 LSD win, Definium modeled up to $70,000 a year for a therapy that could fill a clinical shift
New York City-based biotechnology firm Definium Therapeutics has reached a pivotal juncture in the development of its flagship psychedelic candidate,…
Read More
Before its recent Phase 3 LSD win, Definium modeled up to $70,000 a year for a therapy that could fill a clinical shift
The pharmaceutical landscape for psychiatric care is currently witnessing a paradigm shift as New York City-based Definium Therapeutics advances its…
Read More
Recent Biotech Bi-Weekly Highlights Breakthroughs in Alzheimer’s Modeling and Lab Automation, Fueling Drug Discovery Hopes
In a significant development for neurodegenerative disease research, 28bio, a biotechnology firm based in Los Angeles, USA, has announced the…
Read MoreYOU MAY HAVE MISSED
